 G1 Therapeutics Inc NASDAQ: GTHX has initiated the PRESERVE 3 Phase 2 study evaluating Cosela trilaciclib in patients with untreated, locally advanced, or metastatic urothelial carcinoma mUC. Cosela will be administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy. 